Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer

BACKGROUND: We correlated the tumor proportion score (TPS) of programmed cell death ligand 1 (PD‐L1, SP263 or 22C3) expression with the disease control rate (DCR, partial remission and stable disease), and progression free survival (PFS) after nivolumab or pembrolizumab treatment. METHODS: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Seongho, Choi, Yoo‐Duk, Kim, Jieun, Kho, Bo‐Gun, Park, Cheol‐Kyu, Oh, In‐Jae, Kim, Young‐Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996995/
https://www.ncbi.nlm.nih.gov/pubmed/31841269
http://dx.doi.org/10.1111/1759-7714.13284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996995/
https://www.ncbi.nlm.nih.gov/pubmed/31841269
http://dx.doi.org/10.1111/1759-7714.13284

Ejemplares similares